New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 --PASADENA, CALIF., March ...
Lixte announces online publication of new pre-clinical data in BioXriv
LIXTE Biotechnology (LIXT) announced online publication of new pre-clinical data in BioXriv and International Journal of Pharmaceutics ...
Morningstar5d
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
As published in BioXriv, scientists at the Netherlands Cancer Institute have discovered an enzyme that mediates the conversion of LB-100 into the active metabolite endothall. Accordingly ...